The BAs evaluated (at 50 μM—the lowest concentration shown to affect CD8+ T-cell function in previous studies [15]) demonstrated minimal effect on CLL-mediated immunosuppression (Figure 4, Supplementary Figure S2). The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.